Buscar en
Medicina Clínica (English Edition)
Toda la web
Inicio Medicina Clínica (English Edition) Outcomes of unrelated donor stem cell transplantation with or without anti-thymo...
Journal Information
Vol. 157. Issue 8.
Pages 380-384 (October 2021)
Share
Share
Download PDF
More article options
Visits
1
Vol. 157. Issue 8.
Pages 380-384 (October 2021)
Brief report
Outcomes of unrelated donor stem cell transplantation with or without anti-thymocyte globulin used as graft-versus-host disease prophylaxis in patients with acute leukaemia and myelodysplastic syndrome
Resultados del trasplante de progenitores hematopoyéticos de donante no emparentado con o sin globulina antitimocítica como profilaxis de la enfermedad del injerto contra receptor en pacientes con leucemia aguda y síndrome mielodisplásico
Visits
1
Georgina Genera,
Corresponding author
ggener@iconcologia.net

Corresponding author.
, Montserrat Batllea, Mireia Morgadesa, María-José Jiméneza, Christelle Ferràb, Josep-Maria Riberac
a Servicio de Hematología Clínica, Institut Català d’Oncologia-Hospital Germans Trias i Pujol, Institut de Recerca Contra la Leucèmia, Josep Carreras, Barcelona, Spain
b Universitat de Vic, Universitat Central de Catalunya, Vic, Spain
c Universitat Autònoma de Barcelona, Badalona, Spain
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Tables (2)
Table 1. Baseline patient characteristics.
Table 2. Infectious complications according to the treatment group.
Show moreShow less
Abstract
Background and purpose

Graft-versus-host disease (GVHD) and infections are complications after allogeneic stem cell transplantation (alloSCT). Anti-thymocyte globulin (ATG) is a strategy used as prophylaxis for GVHD. The study analyses the outcomes and frequency of infections with or without ATG after an unrelated donor alloSCT in patients with acute leukaemia and myelodysplastic syndrome.

Patients and methods

Retrospective study of patients receiving an unrelated donor alloSCT between December 2007 and April 2019. The main outcomes were analysed according to use or not of ATG.

Results

Sixty-six patients were included. No significant differences were found between the ATG group (n = 50) vs. no-ATG group (n = 16) in overall survival, cumulative incidence of relapse, cumulative incidence of non-relapse mortality or cumulative incidence of acute GVHD or chronic GVHD. There was a greater frequency of infections in the ATG group (60% vs. 19%, p = .004).

Conclusions

In this study, no differences were shown in the main outcomes of alloSCT based on the use of ATG, although more infections were documented in the ATG group.

Keywords:
Graft-versus-host disease
Anti-thymocyte globulin
Allogeneic stem cell transplantation
Unrelated donor
Resumen
Fundamento y objetivo

La enfermedad del injerto contra el receptor (EICR) y las infecciones son complicaciones del trasplante alogénico de progenitores hematopoyéticos (alo-TPH). La globulina antitimocítica (ATG) es una estrategia empleada para la profilaxis de la EICR. Este estudio analiza los resultados y la frecuencia de infecciones en función del uso de ATG, después de un alo-TPH de donante no emparentado (DNE) en pacientes con leucemia aguda y síndrome mielodisplásico.

Pacientes y método

Estudio retrospectivo de pacientes que recibieron un alo-TPH de DNE entre diciembre 2007 y abril 2019. Se compararon los principales resultados en función del uso de ATG.

Resultados

Se incluyó a 66 pacientes. No se encontraron diferencias significativas en el grupo ATG (n = 50) frente al no-ATG (n = 16) en supervivencia global, incidencia acumulada de recaída, mortalidad no debida a recaída o incidencia acumulada de EICR aguda o crónica. Hubo mayor frecuencia de infecciones en el grupo ATG (60% frente a 19%, p = 0,004).

Conclusiones

En este estudio no se demostró diferencia en los principales resultados del alo-TPH en función del uso de ATG, pero hubo más infecciones en el grupo que recibió ATG.

Palabras clave:
Enfermedad injerto contra receptor
Globulina antitimocítica
Trasplante alogénico de progenitores hematopoyéticos
Donante no emparentado

Article

These are the options to access the full texts of the publication Medicina Clínica (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Medicina Clínica (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.medcle.2020.01.013
No mostrar más